Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER 4 long-term safety and efficacy of Mim8 in haemophilia A
jRCT2041230047Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of denecimig in hemophilia A (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events (TEAEs). Started Feb 2023; status: active, not recruiting.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2041230047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230047.